GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801
Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β
inhibitor, as a single agent and in combination with cytotoxic agents, in patients with
refractory cancers.